Pivotal readout
Novartis reports two-year ianalumab data showing deeper control of Sjögren's disease
In the NEPTUNUS extension, patients on monthly ianalumab had an average ESSDAI drop of 7.5 points by week 108, and 65.1% reached low disease activity. Those who moved from placebo to the drug at week 60 also improved, and adverse event rates were similar across arms. Several regulators are reviewing ianalumab, and Novartis expects an FDA decision in 2026.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.